Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children With <i>Mycoplasma pneumoniae</i> Infection

Wu, Tsung-Hua; Wang, Nancy M.; Liu, Fang-Ching; Pan, Haiyan; Huang, Fang‐Liang; Fang, Yu-Ping; Chiang, Ting-Wei; Yang, Yuying; Song, Chiah-Sing; Wu, Hsiang-Chin; Lee, Chun-Yi

doi:10.1093/ofid/ofab416

Cited by 7 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M. pneumoniae carry a total of 816,394 bp base pairs with 687 genes on the circulating double strands of DNA function to maintain their viability and reproduction [ 80 ]. Molecular epidemiology investigations of M. pneumoniae and macrolide susceptibility have been conducted in a wide range of geographical and temporal contexts [ 24 , 81 , 82 , 83 , 84 ]. Most investigations showed that MRMP usually had specific point mutations in the peptidyl transferase loop of 23S rRNA, as well as insertions or deletions in ribosomal proteins L4 and L22 [ 9 ].…”

Section: Prediction and Early Recognitionmentioning

confidence: 99%

Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management

Tong

Huang

Zheng

et al. 2022

JCM

View full text Add to dashboard Cite

Refractory Mycoplasma pneumoniae pneumonia (RMPP) is a severe state of M. pneumoniae infection that has attracted increasing universal attention in recent years. The pathogenesis of RMPP remains unknown, but the excessive host immune responses as well as macrolide resistance of M. pneumoniae might play important roles in the development of RMPP. To improve the prognosis of RMPP, it is mandatory to recognize RMPP in the early stages, and the detection of macrolide-resistant MP, clinical unresponsiveness to macrolides and elevated proinflammatory cytokines might be clues. Timely and effective anti-mycoplasmal therapy and immunomodulating therapy are the main strategies for RMPP.

show abstract

Section: Prediction and Early Recognitionmentioning

confidence: 99%

Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management

Tong

Huang

Zheng

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“… 1 Mycoplasma pneumoniae (MP) is a common cause of CAP in children and adolescents, accounting for about 10–30% of the cases. 2 , 3 MP infection can cause a variety of clinical symptoms, including fever, headache, cough, etc. 4 Several serious respiratory illnesses caused by MP have also been documented, such as pleural effusion, acute respiratory distress syndrome, and lung abscesses.…”

Section: Introductionmentioning

confidence: 99%

Construction of a Nomogram for Identifying Refractory Mycoplasma pneumoniae Pneumonia Among Macrolide-Unresponsive Mycoplasma pneumoniae Pneumonia in Children

Xie¹,

Zhang²,

Cui³

et al. 2022

JIR

View full text Add to dashboard Cite

Objective The individualized prediction of treatment regimens of macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) is scarce. The aim of this study was, therefore, to evaluate the relevant data of patients and construct a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia (RMPP) among children continued to be treated with macrolide after the confirmation of MUMPP, providing a reference for the choice of treatment regimen. Methods We performed a retrospective study involving 162 children who continued to be treated with macrolide (azithromycin) after the confirmation of MUMPP without antibiotic changes between January 2020 and January 2022. We collected data on clinical feature, hospitalization period, treatments, laboratory data, extrapulmonary symptoms, parapneumonic effusion, and connections with other respiratory pathogens. In addition, the independent risk factors for RMPP were determined through univariate and multivariate analyses, and then a nomogram was constructed and validated. Results In this study, the multivariate logistic regression analysis showed that age, leukocyte count, neutrophil proportion, serum procalcitonin, and lactate dehydrogenase were independent risk factors for RMPP. Using the five independent associated factors, the nomogram for identification of RMPP was constructed. Moreover, the area under the ROC curve (AUC) was 0.925 (95% CI: 0.882–0.968) for the nomogram showing excellent discrimination. The calibration curve, close to the 45-degree line, exhibited good calibration of nomogram. Conclusion We constructed and validated a visual and user-friendly nomogram for individualized prediction of RMPP risk in children who continued to be treated with macrolide after the confirmation of MUMPP based on five variables. According to the nomogram model, continuation of macrolide should be considered rather than second-line antibiotics including tetracyclines (doxycycline or minocycline) and fluoroquinolones for MUMPP children with low predictive values.

show abstract

Mycoplasma pneumoniae multilocus variable-number tandem-repeat analysis genotypes are associated with inflammatory biomarker levels in children with lower respiratory tract infections

Berlot

Mrvič

Keše

2022

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The multilocus variable-number tandem-repeat analysis (MLVA) typing method is commonly used in Mycoplasma pneumoniae ( M. pneumoniae ) epidemiology. It remains unknown if clinical manifestations of lower respiratory tract infections (LRTI) in children differ between different MLVA genotypes. We aimed to determine if specific M. pneumoniae MLVA genotypes indicate the severity of LRTI in children. We performed a retrospective study of children younger than 18 years with signs of acute M. pneumoniae LRTI from January 1, 2009, to December 31, 2014. All patients who were PCR-positive for M. pneumoniae from pharyngeal swabs and had MLVA genotype successfully defined were included in the study. We compared the epidemiological and clinical data of children infected with different MLVA genotypes. In total, 429 patients (mean age 7.4 years, SD 3.4 years; 54% boys) met the study inclusion criteria. We compared the data of patients infected with the three most common MLVA types: MLVA-3,5,6,2 (86/429), MLVA-3,6,6,2 (71/429) and MLVA-4,5,7,2 (256/429). MLVA-3,5,6,2-infected patients over 5 years of age presented with a significantly higher median C-reactive protein level (34 vs 23 vs 19 mg/L, p = .008) and a higher median white blood cell count (9.4 vs 7.9 vs 8.5 × 10 9 /L, p = .040) compared to MLVA-3,6,6,2- and MLVA-4,5,7,2-infected patients. No such difference was observed in the group of younger than 5 years. The results from our large cohort indicate that different MLVA genotypes may have different pathogenic potential and that children with MLVA-3,5,6,2 LRTI may present with higher inflammatory marker levels in comparison with other MLVA types.

show abstract

Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children With Mycoplasma pneumoniae Infection

Cited by 7 publications

References 32 publications

Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management

Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management

Construction of a Nomogram for Identifying Refractory Mycoplasma pneumoniae Pneumonia Among Macrolide-Unresponsive Mycoplasma pneumoniae Pneumonia in Children

Mycoplasma pneumoniae multilocus variable-number tandem-repeat analysis genotypes are associated with inflammatory biomarker levels in children with lower respiratory tract infections

Contact Info

Product

Resources

About